Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke | Zendy

Mar HernándezGuillamón | Zendy; Lidia GarcíaBonilla | Zendy; Montse Solé | Zendy; Victoria Sosti | Zendy; Mireia Parés | Zendy; Mireia Campos | Zendy; Arantxa OrtegaAznar | Zendy; Carmen Domı́nguez | Zendy; Marta Rubiera | Zendy; Marc Ribó | Zendy; Manuel Quintana | Zendy; Carlos A. Molina | Zendy; José ÁlvarezSabín | Zendy; Anna Rosell | Zendy; Mercedes Unzeta | Zendy; Joan Montaner | Zendy

Open Access

Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke

Author(s) -

Mar HernándezGuillamón,

Lidia GarcíaBonilla,

Montse Solé,

Victoria Sosti,

Mireia Parés,

Mireia Campos,

Arantxa OrtegaAznar,

Carmen Domı́nguez,

Marta Rubiera,

Marc Ribó,

Manuel Quintana,

Carlos A. Molina,

José ÁlvarezSabín,

Anna Rosell,

Mercedes Unzeta,

Joan Montaner

Publication year - 2010

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.110.584623

Subject(s) - medicine , stroke (engine) , tissue plasminogen activator , adverse effect , gastroenterology , mechanical engineering , engineering

Vascular adhesion protein-1 (VAP-1) is a cell surface and circulating enzyme involved in recruitment of lymphocytes and neutrophils through its semicarbazide-sensitive amine oxidase (SSAO) activity. We aimed to study plasma VAP-1/SSAO activity in relation to the risk for intracranial bleeding complications in patients with stroke treated with tissue plasminogen activator (tPA), the greatest safety concern with this treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research